Back in June, rumors swirled that Horizon Pharma may be gearing up for some more M&A. And that M&A is here.

Perrigo has a new major shareholder--one that has its own ideas about how to turn the struggling business around.

Bayer is closing in on a deal for agrichemicals giant Monsanto--and it’s reportedly mulling over a divestment that could help it get there.

Now that Valeant CEO Joseph Papa has renegotiated deals with creditors and rejigged his team, he’s ready to sell some assets to pay off debt--and that might…

GlaxoSmithKline had no shortage of critics back in 2014 when it signed the deal to offload its oncology assets and take on Novartis’ vaccines business. But the…

Medivation CEO David Hung fought hard for higher buyout bids. Now, he's set to collect more than $350 million when Pfizer closes its $14 billion deal.

Pharma mergers might boost profits. But long-term value? Think again, because big mergers hurt innovation. That’s the claim--and now, researchers have some…

Novartis is getting closer to unloading its $14 billion stake in crosstown rival Roche. Big investors have been shopping the sale, and bankers could assemble…